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The function of antibodies (Abs) involves specific binding to antigens (Ags) and activa-
tion of other components of the immune system to fight pathogens.The six hypervariable
loops within the variable domains of Abs, commonly termed complementarity determining
regions (CDRs), are widely assumed to be responsible for Ag recognition, while the con-
stant domains are believed to mediate effector activation. Recent studies and analyses of
the growing number of available Ab structures, indicate that this clear functional separation
between the two regions may be an oversimplification. Some positions within the CDRs
have been shown to never participate in Ag binding and some off-CDRs residues often con-
tribute critically to the interaction with the Ag. Moreover, there is now growing evidence
for non-local and even allosteric effects in Ab-Ag interaction in which Ag binding affects
the constant region and vice versa. This review summarizes and discusses the structural
basis of Ag recognition, elaborating on the contribution of different structural determinants
of the Ab to Ag binding and recognition. We discuss the CDRs, the different approaches
for their identification and their relationship to the Ag interface. We also review what is
currently known about the contribution of non-CDRs regions to Ag recognition, namely the
framework regions (FRs) and the constant domains.The suggested mechanisms by which
these regions contribute to Ag binding are discussed. On the Ag side of the interaction,
we discuss attempts to predict B-cell epitopes and the suggested idea to incorporate Ab
information into B-cell epitope prediction schemes. Beyond improving the understanding
of immunity, characterization of the functional role of different parts of the Ab molecule
may help in Ab engineering, design of CDR-derived peptides, and epitope prediction.
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INTRODUCTION
Antibodies (Abs) have two distinct functions: one is to bind specif-
ically to their target antigens (Ags); the other is to elicit an immune
response against the bound Ag by recruiting other cells and mol-
ecules. The association between an Ab and an Ag involves myriad
of non-covalent interactions between the epitope – the binding
site on the Ag, and the paratopes – the binding site on the Ab. The
ability of Abs to bind virtually any non-self surface with exquisite
specificity and high affinity is not only the key to immunity but has
also made Abs an enormously valuable tool in experimental biol-
ogy, biomedical research, diagnostics and therapy. The diversity
of their binding capabilities is particularly striking given the high
structural similarity between all Abs. The availability of increas-
ing amounts of structural data in recent years now allows for a
much better understanding of the structural basis of Ab function
in general, and of Ag recognition in particular. This review sur-
veys the recent developments and the current gaps and challenges
in this field. We focus specifically on the current understanding
of the determinants within the Ab structure that contribute to
Ag binding. We first discuss the motivations for, and applications
of, the study of the structural basis of Ag recognition. Then we
describe and discuss the Ab-Ag interface, with specific focus on the
paratopes and the complementarity determining regions (CDRs),
and their role in Ag binding. The last part focuses on the contri-
bution of the non-CDRs parts of the Ab [i.e., framework regions
(FRs) and the constant domains] to Ag binding and on the recent
suggestions regarding non-local and allosteric effects in Ab func-
tion. Over the last few years numerous reviews have addressed
issues that are related or tangential to the topics we review here.
This includes reviews of the engineering of Abs (1), their stability
(2), affinity maturation (3), and isotype selection (4). While these
important topics are relevant to the findings and ideas we review
here, they are beyond the scope of this review.
THE MOTIVATIONS FOR, AND APPLICATIONS OF, THE STUDY
OF Ab-Ag RECOGNITION
UNDERSTANDING IMMUNITY AND AUTOIMMUNITY
The adaptive immune response involves two types of lymphocytes:
T cells, which recognizes Ags that have been processed and their
fragments are presented by MHC molecules, and B cells which pro-
duce soluble Abs that can identify also the intact Ag in its native
form. While the way in which T cells recognize their epitopes
has been extensively studied to a level that enables the successful
prediction of T-cell epitopes (5, 6), the rules that govern Ab-Ag
recognition, including which parts of the Ab structure underlie
Ag recognition and how and why certain determinants on the Ag
are selected as epitopes, are not as well characterized. Understand-
ing the mechanisms that underlie Ab-Ag recognition, therefore, is
crucial for understanding immunity.
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The immune system enables Abs to distinguish between foreign
and self molecules (7). Autoimmune diseases are characterized by
the inappropriate response to self-Ags. It is not always clear what
role is played by Abs and what role is played by other components
of the immune system in autoimmunity. A variety of molecu-
lar mechanisms have been proposed, including sequestered Ags,
molecular mimicry, and polyclonal B-cell activation (8). Better
understanding of the underpinnings of Ab-Ag recognition may
also shed light on these questions.
A MODEL FOR STUDYING BIO-MOLECULAR RECOGNITION
A fundamental characteristic of the immune system is its ability
to continuously generate novel protein recognition sites. Ab-Ag
interfaces, therefore, are often considered a model system for eluci-
dating the principles governing biomolecular recognition (9–13).
For example, Keskin (14) and McCoy et al. (15) used X-ray crystal-
lographic structures of Ab-Ag complexes to elucidate principles of
the molecular architecture of protein–protein interfaces. Other
studies, however, view Ab-Ag interfaces as a specific case that
may not allow for generalization to all types of protein–protein
interfaces (16). Thus, large scale studies of protein–protein inter-
actions often exclude Ab-Ag complexes from the dataset analyzed
(16–19). It is, therefore, important to determine to what extent Ab-
Ag complexes could serve as a general model for protein–protein
interactions.
ANTIBODY ENGINEERING
The specificity of the Ab molecule to its cognate Ag has been
exploited for the development of a variety of immunoassays, vacci-
nations, and therapeutics. Ab engineering may offer to expand the
application of Abs by permitting improvements of affinity (20, 21)
and specificity (22, 23). Understanding of the role each structural
element in the Ab plays in Ag recognition is essential for success-
ful engineering of better binders. The engineering of Abs is also
important for the clinical use of Abs from non-human sources.
Early studies on the use of rodent Abs in humans determined
that they can be immunogenic (24). Humanization by grafting
of the CDRs from a mouse Ab to a human FR is a commonly
used engineering strategy for reducing immunogenicity (25, 26).
In most cases, the successful design of high-affinity, CDR-grafted,
Abs requires that key residues in the human acceptor FRs that are
crucial for preserving the functional conformation of the CDRs
will be back-mutated to the amino acids of the original murine Ab
(26, 27). Several groups (28–30) used the experimentally deter-
mined 3-D structures of Ab-Ag complexes in the Protein Data
Bank (PDB) (31) to determine which residues participate in Ag
recognition and binding. Such knowledge can be exploited to
identify residues that are important for the function of the Ab
in general and for Ag recognition in particular and may guide Ab
engineering (32, 33). Residues that help maintain the functional
conformation of the CDRs, for example, can be used to improve
Ab humanization efforts by CDR-grafting.
Ab EPITOPE PREDICTION
Antibody epitopes (sometimes referred to as B-cell epitopes) are
the molecular structures within an Ag that make specific contacts
with the Ab paratope. B-cell epitopes are used in the development
of vaccines and in immunodiagnostics. Correct identification of
B-cell epitopes within an antigenic protein, may open the door for
the design of molecules (biologic or synthetic) that mimic poten-
tially protective epitopes and could be used to raise specific Abs
or be used as a prophylactic or therapeutic vaccines. Identification
of B-cell epitopes could promote protective immunity in the con-
text of emerging and re-emerging infectious diseases and potential
bioterrorist threats. This may be achieved by choosing from among
the putative epitopes those that may provide immunity (e.g., by
eliciting Abs that hamper the molecular function of pathogenic
Ags). The choice of such epitopes is believed to be relevant for
understanding and controlling protective immunity. In the case of
the vaccinia virus, for example, which was used as smallpox vac-
cine and is the only vaccine that has led to the complete eradication
of an infectious disease from the human population, individuals
possessing a high frequency of memory B-cells specific for major
neutralizing Ags of the vaccinia virus are better protected from
smallpox than individuals with a memory B-cell pool dominated
by specificities for non-protective Ags (34). Thus, understand-
ing the way in which an Ab recognizes its cognate epitope is
of particular interest for vaccine design and disease prevention
(35). Existing tools for identification of Ab epitopes (such as X-
ray crystallography, pepscan, phage display, expressed fragments,
partial proteolysis, mass spectrometry, and mutagenesis analysis)
are not only expensive, laborious, and time consuming but also
fail to identify many epitopes (36). When talking about protein
Ags, most of these methods typically identify linear stretches as
epitopes, while, arguably, most of the epitopes on protein Ags
are conformational and even discontinuous. As for computational
approaches, despite more than 30 years of efforts (37), existing B-
cell epitope prediction methods are not accurate enough (38, 39)
and are, therefore, not widely used. This is exemplified in Figure 1,
in which the structure of hen egg lysozyme (HEL) Ag and three
Abs that bind it are shown (Figures 1A,B), as well as the epitopes
predicted by three different methods (Figure 1C).
In general, current methods are trying to identify epitopic
residues based on the presence of features associated with residues
that bind the Ab (40–50). One possible explanation for the failure
of these methods is that the differences between epitopes and other
residues are not substantial. Indeed, several analyses (51–53) have
shown that the amino-acid composition of epitopes is essentially
indistinguishable from that of other surface-exposed non-epitopic
residues.
This lack of intrinsic properties that clearly differentiate
between epitopic and non-epitopic residues and the fact (demon-
strated in Figure 1) that most of the Ag surface may become a
part of an epitope under some circumstances (54–57) suggest that
epitopes depend, to a great extent, on the Abs that recognize them.
This is exemplified in Figure 1: most of the HEL surface residues
are part of an epitope of at least one Ab (Figures 1A,B), even
though this figure shows only three Abs (out of dozens known to
bind HEL). Almost all the residues predicted to be epitopic may be
considered as correct predictions as they bind some Ab (Figure 1C)
but also as false predictions as they don’t bind the others. Similarly,
predicting that a residue is not in an epitope may be either a true
negative or a false negative, depending on the Ab considered. It
has recently been suggested by us (Sela-Culang et al., submitted)
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FIGURE 1 | Predicted epitopes vs. the actual epitopes of HEL. (A) The 3-D
structure of HEL (CPK representation) together with three Abs (ribbon
representation). PDB IDs 1JHL, 3D9A, and 1MLC were superimposed
according to HEL structure. Epitope residues are colored blue, green, and red
according to the corresponding Ab. Residues that are common to two
epitopes are colored orange. (B) The structure of HEL colored according to
the same three epitopes as in (A), presented in a different orientation. (C) The
structure of HEL colored according to the epitopes predicted by Discotope
(light blue), ellipro (purple), and seppa (pink). Note, not all predicted residues
of Discotope and ellipro are observable in the presented orientation.
and by others (58–60) that predicting epitopes should be done
for a certain Ab. A similar concept was successfully applied in the
case of T-cell epitope prediction methods: these methods do not
examine the Ag for general features. Rather, different predictions
are made, dependent on the specific MHC molecule binding and
presenting the epitope to T cells.
THE ROLE OF CDRs AND THEIR DEFINITION
As shown in Figure 2, Abs are all-beta proteins consisting of four
polypeptide chains: two identical heavy (H) chains and two iden-
tical light (L) chains (61). The light and heavy chains are linked
by disulfide bonds to form the arms of a Y-shaped structure, each
arm is known as a Fab (61). The Fab is composed of two vari-
able domains (VH in the heavy chain and VL in the light chain)
and two constant domains (CH1 and CL) (62). In the pairing of
light and heavy chains, the two variable domains dimerize to form
the Fv fragment which contains the Ag binding site. Within each
variable domain lie six hypervariable loops (63), three in the light
chain (L1, L2, and L3) and three in the heavy chain (H1, H2, and
H3), supported by a conserved FR of β-sheets. The light and heavy
variable domains fold in a manner that brings the hypervariable
loops together to create the Ag binding site or paratope. Two addi-
tional domains of the heavy chain, CH2, and CH3, compose the
Fc region which is responsible for mediating the biological activity
of the Ab molecule.
CDRs IDENTIFICATION
As indicated by their names, CDRs are believed to account for
the recognition of the Ag. Therefore, a major focus in analyz-
ing the structural basis for Ag recognition has been in identifying
the exact boundaries of the CDRs in a given Ab. It is a common
practice to identify paratopes through the identification of CDRs.
Kabat and co-authors (63, 64) were the first to introduce a sys-
tematic approach to identify CDRs in newly sequenced Abs. It was
based on the assumption that CDRs are the most variable regions
between Abs. Therefore, they aligned the (fairly limited) set of Ab
sequences available at that time and identified the most variable
positions. Based on the alignment, they introduced a numbering
scheme for the residues in the hypervariable regions and deter-
mined which positions mark the beginning and the end of each
CDR. As structural data became available, Chothia and Lesk (65,
66) manually analyzed a small number of experimentally solved
3-D structures and determined the structural location of the loop
regions. The boundaries of the FRs and CDRs were determined
and the latter have been shown to adopt a restricted set of confor-
mations, based on the presence of certain residues at key positions
in the CDRs and the flanking FRs. Their finding that Kabat’s defini-
tions of L1 and H1 are structurally incorrect led to the introduction
of the Chothia numbering scheme. With the increase of available
structural data, they ran their analysis anew and introduced a new
definition of L1 (66) in 1989. In 1997 (67), however, they con-
cluded that this correction was erroneous, and reverted to their
original 1987 numbering scheme. While the Kabat and Chothia
schemes treated separately the different families of immunoglob-
ulin domains, Lefranc and colleagues (68, 69) proposed a unified
numbering scheme (referred to as IMGT numbering scheme) for
immunoglobulin variable domain genomic sequences, including
Ab light and heavy variable domains, as well as T-cell receptor vari-
able domains. To correlate between the sequence, structure, and
domain folding behavior of all immunoglobulin variable domains,
the Aho numbering scheme spatially aligned known 3-D structures
of immunoglobulins and unified their numbering (70).
A drawback of the Kabat, Chothia, and IMGT numbering
schemes is that CDRs length variability takes into account only
the most common loop lengths; While both Kabat and Chothia
schemes accommodate insertions with insertion letters (e.g., 27A),
the IMGT scheme avoids the use of insertion codes for all but the
least common very long loops, and the Aho numbering scheme
places insertions and deletions symmetrically around a key posi-
tion. However, Abs with unusually long insertions may be hard
to annotate using these methods and, as a result, their CDRs may
not be identified correctly. For instance, the recently determined
3-D crystal structure of two bovine Abs (71) reveal exceptionally
long H3 CDRs (>60 residues), with long insertions which these
methods cannot accommodate and thus cannot identify the CDRs
of these Abs.
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FIGURE 2 |The structure of an Ab molecule. (A) The 3-D structure of an Ab molecule (PDB ID: 1IGT). (B) A schematic representation of the Ab scaffold.
ARE CDRs GOOD PROXIES FOR THE PARATOPE?
While identification of paratopes is often done through identifica-
tion of CDRs, not all the residues within the CDRs bind the Ag. In
fact, an early analysis of the 3-D structures of Abs suggested that
only 20–33% of the residues within the CDRs participate in Ag
binding (72). In 1996, MacCallum and colleagues (73) performed
a detailed residue-level analysis of Ag contacts. They suggested that
contacting residues are more common at CDRs residues which
are located at the center of the Ag combining site, and that non-
contacting residues within the CDRs correspond with residues that
are important for maintaining the structural conformations of the
hypervariable loops and not necessarily for recognition of the Ag.
Thus, they introduced a mapping of Ag-contacting propensities
for each Ab position and proposed a new definition for CDRs
based on these propensities. Padlan and co-workers (28) utilized
Abs sequence and structure data to perform a by-position sum-
mary of Ag contacts. They found that the residues that are directly
involved in the interaction with the Ag are also, in general, the
most variable ones. They suggested that the residues that inter-
act with the Ag should be called Specificity Determining Residues
(SDRs).
The number of publicly available structures of Ab-Ag com-
plexes increased in recent years to a level that enabled large-scale
analyses. In a recent analysis (29) we utilized all available protein-
Ab complexes in the PDB to identify the structural regions in which
Ag binding actually occurs. This approach was implemented into
a method dubbed Paratome (30, 74) that is based on a multi-
ple structure alignment (MSTA) of all available Ab-Ag complexes
in the PDB. The MSTA revealed regions of structural consen-
sus where the pattern of structural positions that bind the Ag is
highly similar among all Abs. These regions of structural binding
consensus were termed antigen binding regions (ABRs). While
CDRs, as identified by methods such as Kabat (63), Chothia (65),
and IMGT (69), may miss∼20% of the Ag binding residues, ABRs
cover∼96% of the residues that actually bind the Ag (30). To avoid
confusions and cumbersome nomenclature, herein we generically
refer to CDRs, SDRs, and ABRs as “CDRs” unless otherwise spec-
ified. Figure 3 shows an example of CDRs as identified by Kabat,
Chothia, IMGT, and Paratome for one Ab (anti-IL-15, PDB ID:
2XQB), compared to the actual Ag binding residues. It can be seen
that in this example, some of the CDRs (e.g., L3, H3) identified
by the four methods are almost identical, while in other CDRs
(e.g., L2, H1, and H2) there are substantial differences between the
methods. The MSTA of Abs with known 3-D structure also con-
firmed previous observations that there are structural positions
within the CDRs in which none, or only a small percentage of the
Abs contact the Ag. This is shown in Figure 4 where an example
of such a position is marked by a green arrow.
INTEGRALITY VS. MODULARITY
Designed systems are often characterized as either modular or
integral. In a modular system different components, or mod-
ules, function independent of the function of other modules. The
generation of Abs in the immune system is based on combining
different elements, in a way that may be considered modular where
each component is capable of binding the Ag regardless of the
others. However, some analyses suggest that Ag binding warrants
a more integrative view of the relationships between the different
components of the Ab.
The binding-sites of interacting proteins are usually com-
posed of surface patches that have good shape and electrosta-
tic complementary (15, 75, 76). It has been shown that CDRs
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FIGURE 3 | Comparison of different CDR identification methods. The light
(A) and heavy (B) chains of PDB ID 2XQB were numbered according to Kabat
(colored green) and Chothia (colored red) using the Abnum tool
(www.bioinf.org.uk/abs/abnum) and CDRs were extracted according to the
CDR definitions table (www.bioinf.org.uk/abs/#cdrs). CDRs according to
IMGT (colored orange) were identified using the IMGT-gap tool
(www.imgt.org/3Dstructure-DB/cgi/DomainGapAlign.cgi). ABRs according to
Paratome (colored blue) were identified using the Paratome server
(www.ofranlab.org/paratome). Contacts (colored purple) between the Ab and
IL-15 were defined using a 6-Å cutoff value.
are characterized by an amino-acid composition that is different
from that of other protein loops (77) and also from other types
of protein–protein interfaces (58). Thus, one would expect that
epitopes, just like paratopes, should have a distinct amino-acid
composition. However, several recent analyses (51, 53) have shown
that this is not the case: while epitopes differ from other types of
interfaces (10, 29, 60), their amino-acid composition is virtually
the same as that of non-epitopic surface residues.
Several studies have shown that each CDR has its own unique
amino-acid composition, different from the composition of the
other CDRs (52, 58, 78). Additionally, we have shown that each
CDR has a unique set of contact preferences, therefore, favoring
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FIGURE 4 | Ab positions that contact the Ag. (A,B) The lower graphs show
the percentage of Abs with known 3-D structure that have a residue in a given
position (i.e., in other Abs there is a gap in the MSTA in that position). The
upper graphs show the percentage of Abs that contact the Ag out of those
Abs that have a residue in that position. (A) Depicts the heavy chain and
(B) depicts the light chain. In the upper graphs, the ABRs are colored red and
the FRs are colored blue. An example of a position within an ABR that is not
in contact with the Ag in any of the Abs, is marked by a green arrow. An
example of a position in the FRs that is in contact with the Ag in many (8%) of
the Abs is marked by an orange arrow. (C) The Ab Fv domain (PDB ID: 1QFU)
is colored according to the percentage of all Abs with known 3-D structure in
which the residue in that position is in contact with the Ag: from red (100% of
the Abs) to blue (0%). ABR residues are presented as lines. The definition of
the ABRs is according to the Paratome server. A 6-Å cutoff value was used to
define residues in contact. Percentages of contacts were calculated based on
an MSTA of all protein Ab-Ag complexes in the PDB (30).
certain amino-acids over others (52). Dividing epitope residues
into six subsets according to the CDR they bind, we found that
each of the subsets has a distinct amino-acid composition, distin-
guishable from non-epitope surface (52). In other words, when the
six subsets of epitope residues are considered together the unique
composition of each subset disappears so that the overall amino-
acid composition of the entire epitope is indistinguishable from
the rest of the surface. Pathogenic epitopes may have evolved to
resemble Ag surface to escape recognition. On the other hand, the
integration of the six CDRs together, each with its own unique
amino-acid composition and contact preferences, could be the
evolutionary response of the immune system that enables Abs to
recognize virtually any surface patch on the Ag.
Despite this integrated effect of the CDRs, Abs can be also con-
sidered as a modular system, composed of different elements (such
as the Fab, VH and VL, or the six CDRs), which may bind the Ag
on their own. Such smaller Ab fragments that retain Ag binding
affinity and specificity, hold a great potential for drug design (79–
81) as they have improved pharmacokinetics, tissue and tumor
penetration, and can be produced more economically (80, 81).
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They may also be combined with other fragments to yield better
binders. Although such smaller fragments cannot induce effector
function such as complement activation (due to the lack of the
constant domains), they may neutralize the targeted Ag. Fab and
single-chain variable (scFv) fragments usually maintain specific
binding to the Ag (82). VH and VL fragments usually show sticky
behavior, low solubility, and reduced Ag binding affinity (83–85),
although, they sometime retain specificity to the Ag (83, 85–87).
The CDRs may provide additional level of modularity. Accord-
ing to the commonly accepted hotspot hypothesis, the binding
energy of two proteins is largely determined by a very small num-
ber of critical interface residues (12,88–90). Thus,one may wonder
whether an individual CDR could bind the Ag on its own provided
that it harbors hotspots. Several linear peptides containing one or
more of the CDRs that retained Ag specificity have been reported
(91–98). Although their affinity was usually in the micromolar
range, it could be significantly improved by introducing relatively
minor modifications (91, 99). However, many attempts to isolate
and design such CDR derived peptides failed (100, 101). One pos-
sible reason is that a CDR, on its own, may not fold to the same
conformation as in the context of the entire Fab, which may be cru-
cial for binding. Cyclizing the CDR by adding Cys residues at its
edges was suggested as a solution for this problem (96, 102–104).
Another reason might lie in the fact that many attempts for the
design of CDR-derived peptides are made based on CDR-H3, as it
is considered to be the most important CDR for Ag binding (67,
105–107). However, the median length of ABR-H2 is substantially
longer than that of H3, and both typically form the same number
of interactions with the Ag (52). In addition, while ABR-H3 was
shown to have the highest contribution to Ag binding energy on
average (52), there are individual cases in which other CDRs are the
dominant ones (52, 102). It is also possible that in some cases the
binding depends on specific contacts from residues in different
CDRs, which may preclude the design of CDR-derived peptides
that maintain specificity. We have shown (102) that CDRs that are
able to bind the Ag on their own have unique characteristics and,
thus, can be computationally identified given the Ab-Ag complex
structure. This may enhance the design of CDR-derived peptides
that are not necessarily based on CDR-H3.
NON-CDR DETERMINANTS THAT HAVE A ROLE IN Ag
BINDING
FR RESIDUES
Within the variable domain, the CDRs are believed to be respon-
sible for Ag recognition, while the FR residues are considered a
scaffold for the CDRs. However, it is now well established that
some of the FR residues may play an important role in Ag binding
(32, 108). As mentioned above, many such FR residues were iden-
tified during the process of Ab humanization by CDR grafting.
While grafting only the CDRs usually results in a significant drop
or a complete loss of binding, the binding affinity can be retained
by back mutating some of the FR residues to the original murine
sequence, emphasizing their role in Ag binding (26, 109–115).
Framework region residues that affect Ag binding can be
divided into two categories. The first are FR residues that contact
the Ag, thus are part of the binding-site (108, 109, 111, 116–123).
Some of these residues are close in sequence to the CDRs (in fact
they may be within the boundaries of CDRs according to some
CDR identification methods, but not according to others, as shown
in Figure 3). Other residues are those that are far from the CDRs
in sequence, but are in close proximity to it in the 3-D structure. In
particular, a loop in the heavy chain FR-3, sometimes referred to as
CDR-H4, accounts for 1.3% of human Ab-Ag contacts (78, 124).
This CDR-H4 is also enriched (in human Abs) in somatic hyper-
mutations (Burkovitz et al., submitted). Figure 4 shows positions
that are not in the CDRs but are in contact with the Ag in many Abs
[e.g., the one marked by an orange arrow (4A), which corresponds
to CDR-H4].
In the second category of FR residues that affect Ag bind-
ing, are residues that are not in contact with the Ag, but affect
Ag binding indirectly (108, 109, 120, 121). These residues can
be further divided to those that are in spatial proximity to the
CDRs, and those that are not. The former are assumed to affect
binding by providing a structural support to the CDRs, enabling
them to adopt the right conformation and orientation, shaping
the binding-site required for Ag binding (32). For example, it has
been suggested that a certain position in heavy chain FR-3, close
in structure but not in sequence to CDR-H1 and CDR-H2, affects
the orientation of CDR-H2 relative to CDR-H1 in such a way that
a large side-chain packs between them and separates them while a
small side-chain allows them to be closer to each other (109, 120).
Nevertheless, this is not always true, as was shown in the case of
the anti-lysozyme D1.3 Ab: while mutating Lys in this position to
either Val, Ala, or Arg resulted in affinity difference, no structural
change was observed (121).
Framework region residues that are more distant from the
paratope are suggested to play a role in maintaining the over-
all structure of the Fv domains (32). However, these FR residues
may also affect the Ag binding-site itself, by directing the relative
orientation of the VH vs. the VL, and thus the orientation of the
CDRs relative to each other (125–128). In particular, FR-2 residues
were shown to play an important role in VH-VL interaction (129).
Moreover, Masuda et al. (130) pointed to a specific position in the
FR-2 loop, which controls the strength of the VH-VL interaction
as well as its dependence on Ag binding. We have shown that the
conformation of this loop changes upon Ag binding more than
other residues in the FRs, and that the binding related confor-
mational changes in this loop are similar in their magnitude to
those of the CDRs (107). The potential role of the VH-VL inter-
face in Ag binding is further supported by the observation that
residues that are in the VH-VL interface (and are not a part of the
Ab-Ag interface), are more likely to be mutated during the somatic
hypermutation process, than residues that are not in either of these
interfaces (Burkovitz et al., submitted).
Understanding the role of FR residues in Ag binding is crucial
for efficient Ab design in general and for humanization in particu-
lar. Specifically, knowing in advance which FR residues may affect
Ag binding, one may consider back-mutating these residues into
their murine sequence, to improve affinity during CDR grafting.
To this end, attempts were made to identify positions that con-
tribute to Ag binding in multiple cases (32, 113, 119). For example,
Haidar et al. (32) used a non-redundant dataset of Ab-Ag complex
structures to identify positions that frequently contact the CDRs,
and combined these positions with those that were back-mutated
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frequently in the humanization literature. The 17 FR positions they
identified were successfully used to design a combinatorial library
for Ab humanization. Additional Abs, for which structures of both
wild-type and a mutant(s) are available, may reveal the structural
mechanisms by which each FR position affects Ag binding.
CONSTANT REGION
Until recently, Ab constant domains were considered responsi-
ble for the isotype and for effector function, such as complement
activation, Fc receptor binding, avidity, and serum half-life (131).
However, many studies now provide a strong evidence for a role
for the constant region in Ag binding (131–147). There are many
examples of Abs with identical variable domains but different
isotypes that bind the same Ag with a different affinity or speci-
ficity (134–146). For instance, two Abs sharing identical variable
domains but expressing different isotypes were shown to bind
tubulin with significantly different affinities (135). Consistent with
these studies, it has been shown that the complex of HEL and the Fv
version of the HyHEL-10 Ab has an order of magnitude lower dis-
sociation constant than the complex of HEL with the Fab version of
this Ab (147). A probable explanation for this phenomenon would
be an allosteric influence of the constant domains on the structure
of the variable domains. Indeed, several structural studies pro-
vided some evidence for such structural effects (133, 146, 147).
For example, Janda et al. (133) analyzed by Circular Dichroism
(CD) spectra four different Ab isotypes of the 3E5 family that share
identical variable domains, and showed that the different isotypes
undergo different structural changes upon binding a common Ag.
Similar results were obtained for anti-nuclear Abs as well: Xia et al.
(146) compared four different isotypes of the PL9–11 anti-nuclear
Ab sharing the same variable region, and found that the changes
in secondary structure content (as revealed by CD analysis) as
well as the wave length shifts of tryptophan fluorescence emission,
upon Ag binding, are both isotype dependent. Recently, Tudor et
al. (144) showed that this allosteric effect may control not only Ag
binding affinity and specificity, but also the epitope recognized.
They showed that two anti-HIV-1 IgG1 and IgA2 Abs with identi-
cal variable regions, recognize only partially overlapping epitopes.
Differences in affinity and specificity of Abs with the same vari-
able region but different isotypes may play a role in autoimmunity
if they occur in a self-reactive Ag. For example, different isotypes
have been shown to be associated with different clinical outcomes
for lupus erythematosus: a set of anti-PL9–11 Abs sharing the same
variable domain but different isotypes were shown to bind DNA
and chromatin, as well as the renal Ags, with different affinities that
were associated with significant differences in renal pathogenicity
in vivo and survival (148).
Several studies have suggested that allosteric effects in Abs may
occur on the other direction as well: structural changes in the
variable region caused by Ag binding may be transferred into the
constant domains, potentially influencing effector activation and
cellular response (131, 149–151). For example, Oda et al. (149)
showed that the binding of staphylococcal protein A (SPA) or
streptococcal protein G (SPG) to the constant region was inhibited
by hapten binding in several Abs. A different example was provided
by Horgan et al. (151) who observed differences in complement
activation of two Abs which differ only in their VH domain.
An allosteric effect in Abs is further supported by a systematic
computational analysis we have performed on all available free
and Ag-bound pairs of structures (107). Many of the Ag-binding-
related structural changes occur distant from the Ag binding-site,
including changes in the relative orientation of the heavy and light
chains in both the variable and constant domains as well as a
change in the elbow angle between the variable and the constant
domains. Moreover, the most consistent and substantial confor-
mational change outside of the binding site was found in a loop in
the heavy chain constant domain, which is a part of the CH1-CL
interface, and is involved in complement binding (152).
What could be the mechanism for these allosteric effects?
Changes in the constant domains sequence (different isotypes of
the same Ab) or in its conformation (e.g., by effector binding) may
lead to a rearrangement of the constant domains relative to each
other and relative to the variable domains, which may result in a
change to the VH-VL relative orientation (72), thus re-shaping the
Ag binding-site (153–155).
The potential influence of the constant region on Ag affin-
ity or specificity suggests that the process of class-switch may be
considered, in combination with somatic hypermutations, as a
mechanism for Ab diversity (131, 132). Engineering of an Ab of
interest is usually associated with the optimization of its affin-
ity to the Ag. Since the constant region may affect this affinity, the
isotype selected should be carefully considered. Moreover, the con-
stant region should be taken into account in vaccine design as well
since different isotypes may bind the pathogenic Ag with different
affinities, thus affecting the response to infection. For example, the
anti HIV-1 IgG1 and IgA2 Abs mentioned above share the same
variable region, nevertheless, they have been shown to block HIV-1
infection differently (144). While IgA2 blocked HIV-1 transcyto-
sis and CD4+ cell infection more efficiently, IgG1 and IgA2 act
synergistically to block HIV-1 transfer from Langerhans cells to T
cells. Thus, it has been suggested that a mucosal IgA-based vaccine
response should complement an IgG-based vaccine response in
blocking HIV-1 transmission.
CONCLUDING REMARKS
As Abs are one of the most versatile naturally occurring biosensors,
it is of high importance to decipher the structural and molecular
mechanisms by which they recognize and bind their Ags. Such
knowledge is crucial for understanding immunity, may enable
better prediction of Ab epitopes, and assist in Ab engineering.
While the commonly accepted view has been that CDRs hold
the key for Ab-Ag recognition, recent findings indicate that not
all the positions in the traditionally defined CDRs are impor-
tant for binding. Furthermore, it has been shown that many
positions that contribute critically to the binding energy reside
outside of the transitional CDRs. Moreover, different CDR iden-
tification methods may often identify radically different stretches
as “CDRs,” indicating that CDRs are not well defined and thus
are not necessarily a good proxy for the binding site. The hyper-
variable loops that accommodate the CDRs differ significantly
from each other on various aspects. Understanding the way in
which their binding preferences are integrated to yield the overall
specificity of the Ab is an intriguing structural and biophysical
challenge.
Frontiers in Immunology | B Cell Biology October 2013 | Volume 4 | Article 302 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sela-Culang et al. Structural basis of antibody-antigen recognition
Accumulation of recent data suggests that elements that may
be spatially distant from the Ag binding site also play a crucial
role in Ag recognition. The unorthodox suggestion that non-local
and even allosteric effects influence epitope recognition warrants
additional analysis and research.
Addressing the open questions regarding the structural basis
of Ag recognition requires additional structural data in the form
of crystal structures of Abs bound to Ags of different types
(proteins, peptides, nucleic acids, and haptens). Large-scale analy-
sis of such structures will allow for the generation and testing of
new hypotheses regarding the way in which Abs find and bind
their epitopes.
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